Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser
| Status: | Recruiting |
|---|---|
| Conditions: | Cardiology, Ocular |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | June 2007 |
A Single-Center, Investigator-Sponsored Pilot Study to Assess Safety and Biologic Activity of Bromfenac Ophthalmic Solution, 0.09%, in Subjects With Diffuse DME Refractory to Laser
This is an investigator-sponsored trial (IST), an open-label pilot study, assessing the
safety and biologic activity of bromfenac in subjects with diffuse DME refractory to laser.
safety and biologic activity of bromfenac in subjects with diffuse DME refractory to laser.
Ten subjects will be enrolled in this study, which will be conducted at Ophthalmic
Consultants of Boston, Boston, MA. All subjects must be diagnosed with diffuse DME that is
either refractory to laser photocoagulation or in patients who have refused laser.
Consented subjects will be screened to determine eligibility. Eligibility will be determined
by the Investigator, a retinal specialist. Only one eye will be chosen as the “study eye.”
Only the study eye will receive bromfenac drops during the study.
Eligible subjects will self-administer bromfenac two times per day (BID) for three months
(treatment period). Subjects will have monthly examinations during the treatment period,
followed by follow up visits at Month 4 and Month 6.
Consultants of Boston, Boston, MA. All subjects must be diagnosed with diffuse DME that is
either refractory to laser photocoagulation or in patients who have refused laser.
Consented subjects will be screened to determine eligibility. Eligibility will be determined
by the Investigator, a retinal specialist. Only one eye will be chosen as the “study eye.”
Only the study eye will receive bromfenac drops during the study.
Eligible subjects will self-administer bromfenac two times per day (BID) for three months
(treatment period). Subjects will have monthly examinations during the treatment period,
followed by follow up visits at Month 4 and Month 6.
Inclusion Criteria:
- Age > 18 years
- Center-involved macular edema secondary to diabetes mellitus
Exclusion Criteria:
- Study eye with edema amenable to focal laser
- Treatment with laser, intraocular steroids, and anti-VEGF agents within 90 days
- Current eye infections
We found this trial at
1
site
Click here to add this to my saved trials
